New Risk • Aug 21
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr15m free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (kr24.7m market cap, or US$2.61m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Jul 22
Spermosens AB (publ) to Report Q2, 2026 Results on Aug 20, 2026 Spermosens AB (publ) announced that they will report Q2, 2026 results on Aug 20, 2026 Announcement • Jul 01
Spermosens Provides Update on Ongoing Generation 3 Clinical Study of Juno-Checked Spermosens AB provided an update on the ongoing clinical study of JUNO-Checked Generation 3 at the Reproductive Medicine Centre (RMC) in Malmö. Recruitment is progressing ahead of plan, with 43 patients included to date. The Company's ambition remains, as previously communicated, to complete the study during 2026. The Generation 3 clinical study is a central element in the Company's strategy to demonstrate the clinical value of JUNO-Checked and to pursue commercialization through partnerships. The study evaluates JUNO-Checked, which measures the sperm cell's ability to bind to the egg, in couples undergoing IVF treatment. The clinical data forms the basis for these partner discussions, which the Company continues to advance in parallel with the study. Recruitment has progressed faster than expected so far, supported by a strong collaboration with the clinic and a high willingness among patients to participate. Recruitment will pause during the clinic's summer break and resume mid August. In parallel with the study, the Company is adjusting the parameters of how the test is performed to produce the most accurate results. Validating a new diagnostic technology is a demanding process, and as with any clinical study the outcome and timing are not certain. Spermosens will participate in the Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London on 5-8 July 2026. The Company has been selected to present the results of its first clinical study, completed in 2025 with the second-generation JUNO-Checked sensor, and will meet companies active in the field. 
